References and Notes Supporting Online Material Materials and Methods Som Text Figs. S1 to S6 Tables S1 to S4 Gender Disparity in Liver Cancer Due to Sex Differences in Myd88-dependent Il-6 Production

Hepatocellular carcinoma (HCC), the most common liver cancer, occurs mainly in men. Similar gender disparity is seen in mice given a chemical carcinogen, diethylnitrosamine (DEN). DEN administration caused greater increases in serum interleukin-6 (IL-6) concentration in males than it did in females. Furthermore, ablation of IL-6 abolished the gender differences in hepatocarcinogenesis in mice. DEN exposure promoted production of IL-6 in Kupffer cells (KCs) in a manner dependent on the Toll-like receptor adaptor protein MyD88, ablation of which also protected male mice from DEN-induced hepatocarcinogenesis. Estrogen inhibited secretion of IL-6 from KCs exposed to necrotic hepatocytes and reduced circulating concentrations of IL-6 in DEN-treated male mice. We propose that estrogen-mediated inhibition of IL-6 production by KCs reduces liver cancer risk in females, and these findings may be used to prevent HCC in males.

[1]  I. Chaudry,et al.  Tissue compartment-specific role of estrogen receptor subtypes in immune cell cytokine production following trauma-hemorrhage. , 2007, Journal of applied physiology.

[2]  A. Dolganiuc,et al.  Critical role of toll-like receptors and the common TLR adaptor, MyD88, in induction of granulomas and liver injury. , 2006, Journal of hepatology.

[3]  M. Karin,et al.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[4]  M. Soresi,et al.  Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma. , 2006, World journal of gastroenterology.

[5]  I. Chaudry,et al.  MyD88 and Src Are Differentially Regulated in Kupffer Cells of Males and Proestrus Females Following Hypoxias , 2006, Molecular medicine.

[6]  S. Volinia,et al.  Gene Expression Analysis in HBV Transgenic Mouse Liver: A Model to Study Early Events Related to Hepatocarcinogenesis , 2006, Molecular medicine.

[7]  S. Akira,et al.  Pathogen Recognition and Innate Immunity , 2006, Cell.

[8]  V. Nizet,et al.  Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer , 2006, Cell.

[9]  Masahiro Ito,et al.  Serum cytokine and soluble cytokine receptor levels in patients with non‐alcoholic steatohepatitis , 2006, Liver international : official journal of the International Association for the Study of the Liver.

[10]  Michael Karin,et al.  NF-κB: linking inflammation and immunity to cancer development and progression , 2005, Nature Reviews Immunology.

[11]  Michael Karin,et al.  IKKβ Couples Hepatocyte Death to Cytokine-Driven Compensatory Proliferation that Promotes Chemical Hepatocarcinogenesis , 2005, Cell.

[12]  Kevin J. Tracey,et al.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal , 2005, Nature Reviews Immunology.

[13]  宁北芳,et al.  疟原虫var基因转换速率变化导致抗原变异[英]／Paul H, Robert P, Christodoulou Z, et al//Proc Natl Acad Sci U S A , 2005 .

[14]  M. Sherman.  Hepatocellular carcinoma: epidemiology, risk factors, and screening. , 2005, Seminars in liver disease.

[15]  S. Thorgeirsson,et al.  Application of comparative functional genomics to identify best-fit mouse models to study human cancer , 2004, Nature Genetics.

[16]  Francesco Donato,et al.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors. , 2004, Gastroenterology.

[17]  Josepa Ribes,et al.  Primary liver cancer: worldwide incidence and trends. , 2004, Gastroenterology.

[18]  R. Taub.  Liver regeneration: from myth to mechanism , 2004, Nature Reviews Molecular Cell Biology.

[19]  Y. Ben-Neriah,et al.  NF-κB functions as a tumour promoter in inflammation-associated cancer , 2004, Nature.

[20]  M. Şahin,et al.  Effects of Gender on the Severity of Sepsis , 2004, Surgery Today.

[21]  L. Weber,et al.  Hepatotoxicity and Mechanism of Action of Haloalkanes: Carbon Tetrachloride as a Toxicological Model , 2003, Critical reviews in toxicology.

[22]  T. Asahara,et al.  Sex Hormone Dependency of Diethylnitrosamine‐induced Liver Tumors in Mice and Chemoprevention by Leuprorelin , 2001, Japanese journal of cancer research : Gann.

[23]  Alberto Mantovani,et al.  Inflammation and cancer: back to Virchow? , 2001, The Lancet.

[24]  W. Ewens.  Genetics and analysis of quantitative traits , 1999 .

[25]  N. Ghebranious,et al.  Hepatitis B injury, male gender, aflatoxin, and p53 expression each contribute to hepatocarcinogenesis in transgenic mice , 1998, Hepatology.

[26]  J. Peschon,et al.  Initiation of liver growth by tumor necrosis factor: deficient liver regeneration in mice lacking type I tumor necrosis factor receptor. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[27]  E. Furth,et al.  Liver Failure and Defective Hepatocyte Regeneration in Interleukin-6-Deficient Mice , 1996, Science.

[28]  G. Williams,et al.  N-nitrosodiethylamine mechanistic data and risk assessment: bioactivation, DNA-adduct formation, mutagenicity, and tumor initiation. , 1996, Pharmacology & therapeutics.

[29]  B Stein,et al.  Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta , 1995, Molecular and cellular biology.

[30]  I. Kovalszky,et al.  Modification of DENA-induced hepatocarcinogenesis by CCl4 cirrhosis. Comparison of the marker enzyme patterns. , 1992, Carcinogenesis.

[31]  I. Forgacs.  GASTROENTEROLOGY , 1988, The Lancet.

[32]  W. Gardner,et al.  Carcinogenesis , 1961, The Yale Journal of Biology and Medicine.